OR42-3 Morbidity in a Multisite Retrospective Study of Cross-Sex Hormone-Treated Transgender Persons

Program: Abstracts - Orals, Poster Preview Presentations, and Posters
Session: OR42-Disorders of Sex Development and Transgender Medicine
Tuesday, June 24, 2014: 9:30 AM-11:00 AM
Presentation Start Time: 10:00 AM
W185 (McCormick Place West Building)
Henk Asscheman, MD, PHD1, Guy G. T'Sjoen, MD, PhD2 and Louis J Gooren, MD, PhD3
1HAJAP, Amsterdam, Netherlands, 2Univ Hospital Ghent, Gent, Belgium, 3Andro-Consult, Chiangmai, Thailand
Morbidity in cross-sex hormone-treated transgender people

A multisite retrospective cohort study (6 US & 9 European centers).

We studied retrospectively the data on health of trangender subjects (N >2000)  followed for at least 1 year when starting with or already on cross-sex hormone treatment.

Results:Our data  show a large co-morbidity at the start of hormone treatment: in particular > 20% depression and thyroid disease in 2%. Other comorbidity is very variable and appears not different from data on morbidity with simular age. Few deaths were reported. HIV positivity was observed in 3% as expected in Men having Sex with Men (MSM)

Hormone treatment varied in male-to-female transgender persons (MtF): various estrogen preparationa in different ways of administration: patch, gel, oral and intramuscular. Cyproterone acetate (CPA) in Europe and spirolonactone (ALD) were used as anti-androgens. In FtM: testosterone intramuscular short- and longacting and gel, were prescribed in > 90%. Very few side effects were reported. The main serious side effect, venous thrombo-embolism (VTE) was observed in 1% and related to estrogen use. In FtM: acne, muscle problems and weight increase were the main side effects.

Conclusion: Our data show a very reassuring picture of side effects with cross-sex hormone treatment. Our observations are biased because we have no data on those who were lost after few visits (lost to follow up) and those who went to other clinics ("shoppers"). Nevertheless our data confirm the reassuring data from studies with smaller numbers published in the last 10 years.

Disclosure: GGT: Clinical Researcher, Bayer Schering Pharma, Principal Investigator, Pfizer, Inc., Clinician, Ipsen. Nothing to Disclose: HA, LJG

*Please take note of The Endocrine Society's News Embargo Policy at https://www.endocrine.org/news-room/endo-annual-meeting